Log In
Print
BCIQ
Print
Print this Print this
 

AMG 157, MEDI9929

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb that blocks interaction of thymic stromal lymphopoietin (TSLP) with the TSLP receptor
Molecular Target Thymic stromal lymphopoietin (TSLP)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAsthma
Indication DetailsTreat allergic asthma; Treat asthma
Regulatory Designation
Partner AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$50.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today